Last reviewed · How we verify

medac GmbH — Portfolio Competitive Intelligence Brief

medac GmbH pipeline: 1 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
recombinant asparaginase recombinant asparaginase marketed Enzyme Asparagine Oncology
MC0518 MC0518 phase 3 Histone deacetylase (HDAC) inhibitor Histone deacetylase (HDAC) Oncology
methotrexate prefilled syringe methotrexate prefilled syringe phase 3 Antimetabolite Dihydrofolate reductase Oncology, Autoimmune diseases
methotrexate prefilled pen methotrexate prefilled pen phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advenchen Laboratories Nanjing Ltd. · 1 shared drug class
  2. Andrew E. Place, MD · 1 shared drug class
  3. Asan Medical Center · 1 shared drug class
  4. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  5. BeBetter Med Inc · 1 shared drug class
  6. Bristol-Myers Squibb · 1 shared drug class
  7. Centre Oscar Lambret · 1 shared drug class
  8. Acrotech Biopharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for medac GmbH:

Cite this brief

Drug Landscape (2026). medac GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medac-gmbh. Accessed 2026-06-10.

Related